This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Introduction to Bioconjugates and ADC Design and Development (June Booking Form)
14 - 16 June, 2022
Digital Training Course3:00PM-5:30PM BST // 10:00AM-12:30PM EDT

Why attend Introduction to Bioconjugates and ADC Design and Development?

The teams involved in bioconjugate development need both chemists and biologists to work together effectively. This course provides opportunity to better understand both aspects of the science and thus enhance communication within your team. Delegates will cover the key aspects of bioconjugate/ADC design, why each piece is important and how each can synergise to make an optimized product.


The course will be 2.5 hours each day. In addition to the content below there will be (1) break per day as well as time for Q&A and group discussion.


14-16 June, 2022
3:00PM - 5:30PM British Summer Time (BST) // 10:00AM - 12:30PM Eastern Standard Time (EST) // 07:00AM - 09:30AM Pacific Standard Time (PST)

Topics Include

  • Bioconjugation. From a few simple chemical conjugation methods originally available, we have extended the chemistries and also added enzymatic catalysts to conjugate biomolecules
  • Specialized linker designs. While some kind of linker is required, they can be designed to enhance properties of the conjugates, depending upon the “payload” or moiety to be linked together, sometimes incorporating a built-in release mechanism
  • Effect of payload. Selecting a payload for an ADC or nanoparticle to minimize off-target side-effects
  • Selecting a target for and ADC or nanoparticle
  • Gain an overview of the key aspects and design parameters for diverse bioconjugates
  • Scientific terms and acronyms relating to ADCs and bioconjugates will be defined and explained
  • Current state-of-the-art solutions for the various challenges faced in developing an ADC or bioconjugate
  • Specific challenges for particular product formats – vaccines, ADCs, nanoparticles, etc.